NCT05176288View on ClinicalTrials.gov

Avelumab, Palbociclib and Axitinib in Advanced RCC

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 31, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Advanced Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Axitinib

Taken Orally

DRUG

Palbociclib

Taken Orally

DRUG

Avelumab

Intravenous infusion

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Bradley A. McGregor, MD

OTHER